Mitral Valve Repair with MirtaClip Was Feasible and Safe

Transcatheter mitral valve repair (TMVR) with MitraClip was shown feasible and safe, and therefore a viable option for symptomatic patients with severe mitral valve regurgitation of prohibitive risk. In this regard, the procedure alleviates symptoms, cardiac regurgitation and has a potential benefit on ventricular remodeling. However, many patients presented atrial fibrillation (AF) and mitral valve repair evolution has not been properly analyzed in this group.

This study looked at 5613 patients undergoing TMVR with MitraClip. 3555 presented AF (63.3%).

 

These patients were older (80± 9 vs. 77±11 years) and mostly men (55% vs. 50%). They also presented more stroke, kidney function deterioration, dialysis, definite pacemaker, more cardiac failure FC III-IV, hospitalizations for cardiac failure, AMI and worse quality of life. Mortality STS score was also higher (7% vs. 5% p<0.0001).


Read also: Good Outcomes for MitraClip “Off Label”.


Procedural success was similar for both groups, was well as inhospital mortality. However, patients in the AF group stayed longer in hospital.

 

At one-year follow-up, AF patients experienced higher mortality rate or hospitalization for cardiac failure (hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 1.11 to 1.44; p < 0.001). Patients with AF experienced higher mortality rate (HR: 1.44; 95% CI: 1.22 to 1.70; p < 0.001), hospitalization for CF (HR: 1.17; 95% CI: 1.00 to 1.36; p=0.05), stroke (HR: 1.63; 95% CI: 1.01 to 2.64; p=0.047) and bleeding (HR: 1.34; 95% CI: 1.10 to 1.64; p=0.004). Among patients presenting AF, stroke rate was lower compared to anticoagulated patients.

 

Conclusion

Among patients undergoing percutaneous mitral valve repair the presence of atrial fibrillation is normal, and it is associated to worse evolution at one year follow up, despite similar results at hospital level. More studies are needed on early treatment of mitral regurgitation to minimize the development of atrial fibrillation, and to identify therapies to improve these patients’ evolution.

 

Original Title: The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair. Results from the Society of Thoracic Surgeons / American College of Cardiology Transcatheter Valve Therapy Registry.

References: Sameer Arora, et al. J Am Coll Cardiol Intv 2019;12:569–78


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...